These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 21455919)
1. A coordinated synthesis and conjugation strategy for the preparation of homogeneous glycoconjugate vaccine candidates. Grayson EJ; Bernardes GJ; Chalker JM; Boutureira O; Koeppe JR; Davis BG Angew Chem Int Ed Engl; 2011 Apr; 50(18):4127-32. PubMed ID: 21455919 [No Abstract] [Full Text] [Related]
2. Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease. Wright K; Guerreiro C; Laurent I; Baleux F; Mulard LA Org Biomol Chem; 2004 May; 2(10):1518-27. PubMed ID: 15136809 [TBL] [Abstract][Full Text] [Related]
3. O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein. Micoli F; Giannelli C; Di Benedetto R Methods Mol Biol; 2021; 2183():267-304. PubMed ID: 32959249 [TBL] [Abstract][Full Text] [Related]
4. Oligosaccharide Antigen Conjugation to Carrier Proteins to Formulate Glycoconjugate Vaccines. Smith BR; Guo Z Methods Mol Biol; 2021; 2183():305-312. PubMed ID: 32959250 [TBL] [Abstract][Full Text] [Related]
5. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines. Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974 [TBL] [Abstract][Full Text] [Related]
6. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198 [TBL] [Abstract][Full Text] [Related]
7. Click Chemistry Applied to the Synthesis of Salmonella Typhimurium O-Antigen Glycoconjugate Vaccine on Solid Phase with Sugar Recycling. Stefanetti G; Saul A; MacLennan CA; Micoli F Bioconjug Chem; 2015 Dec; 26(12):2507-13. PubMed ID: 26549104 [TBL] [Abstract][Full Text] [Related]
8. Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates. Humpierre AR; Zanuy A; Saenz M; Garrido R; Vasco AV; Pérez-Nicado R; Soroa-Milán Y; Santana-Mederos D; Westermann B; Vérez-Bencomo V; Méndez Y; García-Rivera D; Rivera DG Bioconjug Chem; 2020 Sep; 31(9):2231-2240. PubMed ID: 32809806 [TBL] [Abstract][Full Text] [Related]
9. Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease. Lanzilao L; Stefanetti G; Saul A; MacLennan CA; Micoli F; Rondini S PLoS One; 2015; 10(10):e0139847. PubMed ID: 26445460 [TBL] [Abstract][Full Text] [Related]
10. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628 [TBL] [Abstract][Full Text] [Related]
12. Investigation on Sugar-Protein Connectivity in Salmonella O-Antigen Glycoconjugate Vaccines. De Benedetto G; Salvini L; Gotta S; Cescutti P; Micoli F Bioconjug Chem; 2018 May; 29(5):1736-1747. PubMed ID: 29697244 [TBL] [Abstract][Full Text] [Related]
13. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. Berti F; Micoli F Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591 [TBL] [Abstract][Full Text] [Related]
14. Glycoconjugate vaccines. What next? Stein KE Int J Technol Assess Health Care; 1994; 10(1):167-76. PubMed ID: 8157449 [TBL] [Abstract][Full Text] [Related]
18. Spectroscopic studies of the structure and stability of glycoconjugate vaccines. Jones C; Lemercinier X; Crane DT; Gee CK; Austin S Dev Biol (Basel); 2000; 103():121-36. PubMed ID: 11214231 [No Abstract] [Full Text] [Related]
19. Preparation of synthetic polyoxazoline based carrier and Vibrio cholerae O-specific polysaccharide conjugate vaccine. Farkas P; Korcová J; Kronek J; Bystrický S Eur J Med Chem; 2010 Feb; 45(2):795-9. PubMed ID: 19939517 [TBL] [Abstract][Full Text] [Related]
20. Exploitation of Capsule Polymerases for Enzymatic Synthesis of Polysaccharide Antigens Used in Glycoconjugate Vaccines. Litschko C; Budde I; Berger M; Fiebig T Methods Mol Biol; 2021; 2183():313-330. PubMed ID: 32959251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]